Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen® for the development of next generation biologic drugs that extend the efficacy, safety and half-life of biologic drugs and OncoHist® for the development of novel oncology drugs focused on orphan indications.
If you wish the view the Scheme Document and other related Documents, please click here.
Xenetic is developing a biopharmaceutical pipeline with a multi-billion dollar market potential.
Xenetic has collaborations with leading global biopharma companies, including Baxter International